Antibiotics

PacBio Partners with The European Reference Genome Atlas Initiative

Monday, September 27, 2021 - 2:00pm

Biodiversity is under threat worldwide with a high number of European species at risk of extinction1.

Key Points: 
  • Biodiversity is under threat worldwide with a high number of European species at risk of extinction1.
  • Together, PacBio and ERGA aim to put Europes biodiversity on the path to recovery by 2030, said Neil Ward, Vice President and General Manager of EMEA at PacBio.
  • ERGA seeks to increase coordination across all countries of the European continent, in tandem with international partners, to generate reference-quality, complete and error-free genome assemblies for at least 200,000 plant and animal species - across Europe.
  • Were excited to welcome PacBio to the ERGA initiative and look forward to our coordinated effort to generate complete reference genomes for all European biodiversity, which will accelerate conservation initiatives and advance biodiversity genomics innovation.

Global $13.8 Billion Antimicrobial Resistance Market, 2027 | Opportunity Breakdown by Disease, Pathogen, Drug Class, End-user and Region - ResearchAndMarkets.com

Monday, September 27, 2021 - 12:09pm

The global antimicrobial resistance market was valued at US$ 9.39 billion in 2020, and is estimated to reach US$ 13.8 billion in 2027, with a CAGR of 4.68% from 2021-2027.

Key Points: 
  • The global antimicrobial resistance market was valued at US$ 9.39 billion in 2020, and is estimated to reach US$ 13.8 billion in 2027, with a CAGR of 4.68% from 2021-2027.
  • The emergence and spread of drug-resistant pathogens which have acquired new resistance mechanisms, leading to antimicrobial resistance, continues to threaten our ability to treat common infections.
  • New antibacterial are urgently needed - for instance, to treat carbapenem-resistant gram-negative bacterial infections as identified in the WHO priority pathogen list.
  • Europe was the second largest regional market in the global arena in 2020, supported largely by growing number of antibiotic-resistant infections.

CosmosID Launches Accurate and Easy Functional Microbiome Analysis with New Software Platform, CosmosID-HUB: Microbiome

Friday, September 24, 2021 - 1:36pm

CosmosID , known for the most accurate, multi-kingdom, strain level taxonomic profiling technology, has added a functional analysis module to its popular online user-interface, renamed ' CosmosID-HUB: Microbiome '.

Key Points: 
  • CosmosID , known for the most accurate, multi-kingdom, strain level taxonomic profiling technology, has added a functional analysis module to its popular online user-interface, renamed ' CosmosID-HUB: Microbiome '.
  • "This cutting edge, accurate, easy and fast functional analysis feature is part of our ongoing mission to provide everything researchers need to complete their end-to-end microbiome analysis and lower the barrier to entry for those interested in the field."
  • "We plan to expand CosmosID-HUB continually with the latest tools to enable both taxonomic and functional analysis of microbiomes."
  • CosmosID also offers independently validated, industry-leading pipelines for processing metagenomic data, yielding multi-kingdom, strain-level resolution with leading sensitivity and precision as well as functional characterization.

U.S. Dept. of Health and Human Services Taps Draper to Develop Lung-on-a-Chip Technology to Study SARS-CoV-2

Thursday, September 23, 2021 - 3:00pm

With the contract, Draper will design a model for human airway tissue and adapt its PREDICT96 platform to collect data for SARS-CoV-2 infection studies.

Key Points: 
  • With the contract, Draper will design a model for human airway tissue and adapt its PREDICT96 platform to collect data for SARS-CoV-2 infection studies.
  • The study of respiratory health, diseases and treatments is typically done through animal studies or culture models using animal or human cells.
  • BARDA's ImmuneChip+ program requires that all applicants already have a mature, validated tissue chip, in this case the lung.
  • To develop an organ-on-a-chip, human cells are used to manufacture 3D organ-like structures.

Opentrons Announces $200 Million Series C Round Led by SoftBank Vision Fund 2

Thursday, September 23, 2021 - 1:00pm

Today Opentrons Labworks Inc. has announced SoftBank Vision Fund 2* has led the companys $200 million Series C investment with participation by Khosla Ventures.

Key Points: 
  • Today Opentrons Labworks Inc. has announced SoftBank Vision Fund 2* has led the companys $200 million Series C investment with participation by Khosla Ventures.
  • The Series C round will enable significant investment in the Opentrons platform.
  • OPENTRONS ANNOUNCES KEY TEAM ADDITIONS TO SCALE PLATFORM:
    Myrtle Potter, Chair of the Board of Opentrons Labworks, Inc. Myrtle is currently CEO of Sumitovant.
  • *As of the date of this press release, SoftBank Group Corp. has made capital contributions to allow investments by SoftBank Vision Fund 2 ("SVF 2") in certain portfolio companies.

Global Anti-Infective Drugs Market Report 2021: COVID-19 Implications and Growth to 2030 - ResearchAndMarkets.com

Thursday, September 23, 2021 - 10:07am

The "Anti-Infective Drugs Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anti-Infective Drugs Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Anti-Infective Drugs Global Market Report 2021: COVID-19 Implications and Growth to 2030 covers this critical market and the impact on it from the COVID-19 virus.
  • The global anti-infective drugs market is expected to decline from $132.16 billion in 2020 to $116.4 billion in 2021 at a compound annual growth rate (CAGR) of -11.9%.
  • North America was the largest region in the global anti-infective drugs market, accounting for 50% of the market in 2020.

Camber Spine Launches SPIRA-P and SPIRA-T Implants for National Distribution

Wednesday, September 22, 2021 - 4:35pm

Camber Spine , a leading innovator in spine and medical technologies, has initiated the full national launch of its SPIRA-P Posterior Lumbar Spacer and SPIRA-T Oblique Posterior Lumbar Spacer devices.

Key Points: 
  • Camber Spine , a leading innovator in spine and medical technologies, has initiated the full national launch of its SPIRA-P Posterior Lumbar Spacer and SPIRA-T Oblique Posterior Lumbar Spacer devices.
  • Plus, its uniquely designed surface allows for cell adhesion and bone cell proliferation while its interconnected porosity design mimics bone.
  • Innovative spine and medical technology company Camber Spine Technologies is dedicated to creating surgeon-designed solutions in MIS and minimally disruptive access for the treatment of complex spinal pathology.
  • Incorporating state-of-the-art manufacturing, 3-D printing, and an acute sensitivity to patient anatomy, Camber Spine is making quantum leaps in the spinal fusion market.

IHMA Opens Microbiology Reference Laboratory in Shanghai, China to Further Support Global Anti-Infective Product Discovery and Development

Wednesday, September 22, 2021 - 3:30pm

IHMA has opened a microbiology reference laboratory in Shanghai, China in February of 2021.

Key Points: 
  • IHMA has opened a microbiology reference laboratory in Shanghai, China in February of 2021.
  • This facility will join IHMA locations in the USA, Switzerland and India to allow the company to provide more robust global support for anti-infective product discovery and development.
  • As the leading global microbiology service provider to the biopharmaceutical industry, IHMA utilizes its extensive laboratory and industry expertise to support efficient and effective anti-infective product development.
  • IHMA is a premier provider of reference laboratory services to support anti-infective product discovery and development as well as the development of diagnostic devices that detect bacterial resistance to antimicrobial agents and new technologies as they emerge.

BioChain announces expanded line of NGS characterized bio-samples for oncology researchers

Wednesday, September 22, 2021 - 1:11pm

"At BioChain, we do the upfront work of screening for mutations to ultimately provide this information to further research."

Key Points: 
  • "At BioChain, we do the upfront work of screening for mutations to ultimately provide this information to further research."
  • BioChain now offers ready-to-use, NGS characterized tissue samples for BRCA1, BRCA2, MSI, HPV, EGFR, and KRAS, developing the new mutation-specific bio-samples in response to the growing need and demand from researchers.
  • For oncology researchers studying pathways related to BRCA1 and BRCA2, BioChain offers samples from breast cancer donors characterized using the Paragon genomics BRCA1&2 panel.
  • BioChain offers HPV positive and negative tissue sections of these cancers as control slides for oncology researchers.

GeneDx Announces the Sequencing of More Than 300,000 Clinical Patient Exomes

Tuesday, September 21, 2021 - 7:30pm

GeneDx today announced it has completed clinical genetic exome sequencing for more than 300,000 patients.

Key Points: 
  • GeneDx today announced it has completed clinical genetic exome sequencing for more than 300,000 patients.
  • The rapid acceleration in demand for our exome testing, including nearly 100,000 exomes completed in the last year alone, shows this transition is well underway," said Katherine Stueland, president and CEO of GeneDx.
  • Exome and whole genome sequencing are genetic tests designed to provide a comprehensive look at an individual's DNA.
  • Originally founded by scientists from the National Institutes of Health, GeneDx offers a world-renowned clinical genomics program with particular expertise in rare and ultra-rare genetic disorders.